Pulmonary

Our pulmonary expertise enables you to meet the demands of today and deliver the possibilities of tomorrow. With phase-appropriate analytical methods, innovative device design and exceptional formulation development for both small and macromolecules, we help accelerate your first-in-human timeline and maximize your product’s long-term success.

Pulmonary platforms designed to progress with purpose

Amplify the impact of your product with our pulmonary platform selection process.

Pulmonary drug delivery technologies

The right inhalation device is key to effective therapy. Our detailed, purpose-driven process helps you choose the optimal option.

Pressurized metered-dose inhalers (pMDIs)

As the inventors of the original metered-dose inhaler, we continue to lead the industry in pMDI innovation. We offer extensive development and manufacturing expertise, leveraging this versatile platform to optimize drug delivery to both the lungs and nasal cavity.

Why choose pMDIs?

• Targeted delivery: They deliver medication directly to the affected area, minimizing systemic side effects and ensuring rapid onset of action.
• Ease of use: Multi-dose pMDI devices are patient-friendly, requiring minimal inspiratory effort and offering consistent handling.
• Cost-effectiveness: Compared with other inhalation technologies, pMDIs are a cost-effective and accessible option for patients worldwide.
• Formulation flexibility: pMDIs support a wide range of formulations, including propellant-based suspensions and solutions, accommodating various API requirements.

Dry powder inhalers (DPIs)

We are dedicated to setting new standards in DPI performance for pulmonary biologics combination products. Our expertise in spray drying enables the development of stable, dispersible and flowable powders capable of efficient dose delivery, even for high-dose medications and complex biologics.

Why choose DPIs?

• High payload capacity: DPIs accommodate high drug payloads, making them suitable for a wide range of therapies.
• Room temperature stability: Advanced DPI formulations ensure stability at room temperature, simplifying storage and distribution.
• Inhalation flow independence: Regardless of patient inhalation flow rate, DPIs deliver consistent doses, improving efficacy and patient experience.
• Efficient lung delivery: DPI technology maximizes drug delivery to the lungs, enhancing therapeutic outcomes.

Soft mist inhalers (SMIs)

We offer comprehensive development and manufacturing expertise for SMIs, a patient-friendly inhalation technology that delivers medication as a slow-moving mist.

Why choose SMIs?

• Ease of use: SMIs simplify inhalation therapy, requiring minimal inspiratory effort and eliminating the need for hand-breath coordination.
• Versatile formulation: Aqueous formulations of small and large-molecule drugs, including complex biologics, offer flexibility for your therapeutic needs.
• Enhanced patient adherence: The ease of use and consistent dose delivery of SMIs can contribute to improved patient adherence and therapeutic outcomes.

Nebulizers

We partner with you to rapidly develop and optimize aqueous formulations that can be delivered using off-the-shelf nebulizers.

Why choose nebulizers?

• Patient-friendly design: Nebulizers are designed for ease of use, with features such as silent operation, simple controls and discreet portability.
• Versatile formulation: Aqueous solutions, suspensions and high-viscosity formulations are suitable for nebulizer delivery, accommodating diverse API requirements.
• Efficient drug delivery: Nebulizers offer high payload capacity and increased lung deposition, enhancing the efficacy of your therapy.
• Advanced features: Nebulizers can incorporate innovative features such as dose proportionality and connectivity, optimizing treatment and patient experience.